...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
- Announced the release of the latest version of VIE.gg (https://vie.gg) the Company’s esports wagering platform
- Latest upgrade delivers notable new features, including additional betting options such as Fixed Odds, Pari-mutuel, Fantasy and Pool Betting to complement main P2P option
- Grant Johnson, CEO of Esports Entertainment Group, stated "This is another major milestone for our Company. This is our strongest release ever, with every new feature esports gambling enthusiasts could wish for in a platform..."
DONALD J. MCCAFFREY
President and CEO, Co-Founder
Mr. McCaffrey is President and Chief Executive Officer of Resverlogix Corp. He has over 38 years of corporate management experience including over 18 years in drug discovery & development. Don co-founded Resverlogix in 2001 with Dr. Norman Wong. Don’s expertise in corporate operations has attracted an international team of experts to the company, including world renowned Key Opinion Leaders in the fields of cardiology, endocrinology and nephrology. The company’s lead drug – apabetalone (RVX-208) – is currently in a fully-enrolled, Phase 3 clinical trial – BETonMACE. Due to Don’s efforts, apabetalone has an 8-year lead on the market as the first epigenetic drug for the reduction of Major Adverse Cardiac Events. Don has strategically directed the company in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Shenzhen Hepalink Pharmaceuticals. Don is also the co-founder, President and CEO of Zenith Epigenetics, a private, clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need.
Don’s passion lies in supporting non-profit organizations, especially those that support education and the development of future generations of young scientists. Don’s personal donation to the Mount Royal University contributed to the Roderick Mah Centre for Continuous Learning, which supports student facilities within the health and sciences programs. The building is one of North America’s most environmentally sustainable, technologically advanced and designed for learning.
DR. NORMAN C.W. WONG, B.Sc (Hon), M.Sc, M.D., FRCP
Chief Scientific Officer & Co-Founder
Dr. Wong is Co-Founder and Chief Scientific Officer of Resverlogix Corp. Dr. Wong serves as Professor of Medicine, University of Calgary, a clinician and scientist who specializes in endocrinology, internal medicine, molecular biology, gene/cell therapy and regulation. His numerous academic accomplishments include over 300 published works, including extensive research in the field of epigenetics.
Dr. Wong has served as a medical consultant to Abbott Laboratories, Amgen, Astra Zeneca, B.I., Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Sanofi, and Solvay Pharmaceuticals in the areas of diabetes mellitus, thyroid disease, testosterone treatment and in the development of cholesterol lowering drugs. He is a Director of Zenith Epigenetics, and is a member of the Scientific Advisory Board at Sernova Corp. Dr. Wong’s academic record includes an Undergraduate B. Sc., Masters Degree in medical biochemistry, and a Medical Degree from the University of Calgary.
Norm enjoys spending time with his grandchildren, traveling and cooking.
A. BRAD CANN, CPA, CA, CBV
Chief Financial Officer
Mr. Cann has more than 20 years of experience in a variety of financial and corporate roles. Prior to joining Resverlogix, Mr. Cann was Executive Vice President and Chief Financial Officer of Royal Host Real Estate Investment Trust. Previous to his positions with Royal Host, he was a business consultant and held senior management positions with several companies including Chief Financial Officer of Sulphur Corporation of Canada Ltd. Prior thereto, Mr. Cann held various positions with Kenway Mack Slusarchuk Stewart Chartered Accountants.
Mr. Cann is a Chartered Professional Accountant and a Chartered Business Valuator, and holds a Bachelor of Commerce from the University of Saskatchewan.
Brad is an avid cyclist and triathlete.
DR. MICHAEL SWEENEY, M.D.
Senior Vice President of Clinical Development
Dr. Sweeney, a cardiologist, has a career spanning 35 years in the pharmaceutical industry, including 11 years at Pfizer Inc., holding a variety of senior-level medical and marketing positions, including Senior Director, Urology Global Medical Group Leader and Director of Marketing of the Viagra® Worldwide Team. Prior to joining Resverlogix, Dr. Sweeney was Chief Medical Officer and Vice President of Research and Development at Depomed, Inc. in Silicon Valley. Dr. Sweeney was also the Vice President of Medical Affairs at CV Therapeutics, Inc., where he built the medical affairs department to enable the successful launch of Ranexa® for patients with cardiovascular disease and chronic angina.
Dr. Sweeney holds biochemistry and medical degrees from Liverpool University and an advanced medical research degree from Manchester University in the U.K. Dr. Sweeney also holds post-graduate diplomas in pharmaceutical medicine and pharmaco-epidemiology from the University of London. He is a fellow of the Royal College of Physicians of Edinburgh.
Mike enjoys swimming, cycling, football, the cinema and travelling with his family.
DR. EWELINA KULIKOWSKI, PH.D.
Senior Vice President of Research & Development
Dr. Kulikowski has over 15 years of experience in the biotech industry. She joined Resverlogix in 2005 and currently leads all of the research and development activities at Resverlogix.
Dr. Kulikowski has contributed to the development of lead drug RVX-208 (apabetalone) from its discovery through to the Investigational New Drug application and into clinical development. Dr. Kulikowski has also led projects in oncology, ophthalmology, vascular inflammation and the development of the neurodegenerative program. Dr. Kulikowski has been involved in various aspects of pipeline development including market, reimbursement and pharmacoeconomic surveys, regulatory affairs, commercial and lifecycle management. In 2004, she received her Doctorate in Oncology from the University of Calgary, AB.
Ewelina is an avid cyclist, fluent in Polish and an active member of the Calgary Polish community.
DR. JAN O. JOHANSSON, M.D., PH.D.
Senior Vice President Medical Affairs
Dr. Johansson has 35 years of experience in academia and the pharmaceutical industry of which include small biotechnology and large pharmaceutical companies with expertise in the cardio-metabolic and neurological disease therapeutic areas. Dr. Johansson has served as Chief Medical Officer at Nuvelo, Inc., Vice President, Clinical Research and Development at Lipid Sciences, Inc. and was Co-founder, Vice President, Clinical Affairs and Senior Clinical Research Fellow of Esperion Therapeutics, Inc. From 1995 to 1997, Dr. Johansson was a medical adviser with executive responsibilities at the cardiometabolic division of Pharmacia, Sweden, helping bring LOVAZA/OMACOR and FRAGMIN to the market.
Dr. Johansson earned his M.D. and Ph.D.at the Karolinska Institute in Sweden where he led a successful career as a tenured associate professor at the Karolinska Hospital and as a practicing physician. He has published more than 75 peer-review medical articles and 10 patents. He is a member of several scientific organizations including the American Heart Association and the European Atherosclerosis Society.
Jan enjoys bike-riding and spending time with his grandchildren.
KENNETH LEBIODA, BA
Senior Vice President Business & Corporate Development
Mr. Lebioda has over 30 years of experience in the innovative pharmaceutical industry with leading global companies such as Bristol-Myers Squibb, Hoechst Marion Roussel and Marion Merrell Dow. He held a variety of management positions with these companies in the areas of sales and business development, regulatory affairs, reimbursement and market access.
Mr. Lebioda’s past contributions helped build leading global cardiovascular brands such as Plavix, Pravachol, Cardizem, and Avapro. He is responsible for leading the Company's efforts in product portfolio strategy, pharmacoeconomics, reimbursement, licensing and commercial development.
Ken is an accomplished musician and enjoys travelling with his family.
DR. HENRIK C. HANSEN, PH.D.
Vice President of Intellectual Property
Dr. Hansen joined Resverlogix in 2005 and has 20 years of experience from both academia and industry in basic research, drug discovery and drug development. His areas of expertise include drug discovery, medicinal chemistry, process development and manufacturing of drug substances and drug products under cGMP for clinical use. Dr. Hansen is the inventor of RVX-208 (apabetalone).
Dr. Hansen holds a M.Sc. in Chemical Engineering from the Technical University of Denmark and a Ph.D. in Organic Chemistry from Lund University, Sweden. He has authored or co-authored more than 70 articles and meeting abstracts and is listed as the inventor of 12 patent families.
Henrik is an active runner and nature photographer.
Paul Moon, CPIR
Vice President, Investor Relations and Communications
Paul joined Resverlogix’s leadership team in July 2018 and brings 25 years of public company experience working in multiple industries, including: technology, financial services, real estate, international mining, and oil and gas. Paul has provided strategic investor relations guidance to senior leadership teams across different industries and has a deep understanding of the capital markets. He has been instrumental in developing investor relations and communications strategies to address multiple stakeholders’ needs and to position companies for success.
Prior to joining Resverlogix, Paul served as the Director of Investor Relations, Corporate Communications and Marketing for Pure Technologies, a company developing innovative solutions that help protect critical water infrastructure around the world. Other posts include Director of Investor Relations for Boardwalk REIT, Canada’s largest residential landlord and serving as an investor relations consultant for public and private companies.